Intensity Therapeutics, a late-stage clinical biotechnology company, develops intratumoral therapies for solid tumors using its DfuseRx platform and lead candidate INT230-6. The company has reported encouraging early tumor-clearance signals in clinical trials but remains unprofitable with operating losses of $12.0 million and net losses of $11.6 million in FY2025. Cash reserves of approximately $11.9 million at year-end 2025 provide limited runway amid ongoing negative cash flows. Intellectual property protection includes multiple patents and orphan drug designation for soft tissue sarcoma. Challenges include regulatory approval processes, reimbursement uncertainties, intense competition from larger oncology firms, and the need for substantial additional capital to sustain development and build commercial capabilities. Key upcoming milestones include Phase 3 trial progress, regulatory interactions, and financing events.